We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.24 | 1.35% | 93.08 | 92.10 | 93.20 | 93.18 | 91.92 | 91.97 | 2,031,482 | 16:40:00 |
From May 2019 to May 2024
By Colin Kellaher
Sanofi SA on Tuesday said a phase 3 study of Sarclisa added to the standard-of-care treatment of carfilzomib and dexamethasone met the primary endpoint at its first planned interim analysis in patients with relapsed multiple myeloma.
The Paris drug maker said the addition of Sarclisa showed significantly prolonged progression-free survival compared to carfilzomib and dexamethasone alone in patients with the blood cancer.
Sanofi said there were no new safety signals identified in the study, the second positive phase 3 trial for Sarclisa, adding that it expects the study results to form the basis of regulatory submissions planned for later this year.
Sarclisa is approved in the U.S. in combination with pomalidomide and dexamethasone for the treatment of adults with relapsed refractory multiple myeloma who have received at least two prior therapies.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 12, 2020 09:04 ET (13:04 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
